Dexcom, Inc.

Obalon Therapeutics, Inc.

Reshape Lifesciences Inc.

Medtronic Vascular, Inc.

Biolinq Incorporated

Mark C Brister

Peter C Simpson

Sean T Saint

James H Brauker

James R Petisce

Apurv Ullas Kamath

Neil R Drake

Jack Pryor

Antonio C Llevares

John Nolting

Andrew P Rasdal

Dubravka Markovic

James Patrick Thrower

Paul V Neale

Amy D L VandenBerg

Matthew D Wightlin

Steve Masterson

Vance Swanson

Nelson Quintana

Paul V Goode, Jr

Jacob S Leach

Daniel Steven Kline

Kum Ming Woo

Matthew S Lake

Josefina Nider

Paul D Faucher

Daniel Shawn Codd

Kaushik Aroonkumar Patel

Robert James Boock

Richard Chien Yang

Michael Robert Mensinger

Aarthi Mahalingam

Ying Li

Thomas F McGee

David Michael Petersen

Mark C Shults

Melissa A Nicholas

Luis Pestana

J Michael Dobbles

Monica A Rixman

Daniel J Proctor

Victor Ha

Sheldon Nelson

John Michael Dobbles

Lisa Nguyen

Seth R Brunner

Arthur Chee

David Michael Morelock

George Albert Mansfield

Paul Goode

Joshua Andrew Warner

Betty Wong

Nathan Thomas Balcom

Joshua David Doan

James Kevin Carney

Daiting Rong

Arnold Holmquist

Mohammad Ali Shariati

David K Wong

Madeline Campbell

David L Thompson

Victoria E Carr-Brendel

Rathbun K Rhodes

Michael J Estes

John A Guerre

Eleanor McCarthy

Keoni John Sundseth

Amy Dl VandenBerg

Mark Allan Tapsak

Curtis Hanson

Rathburn K Rhodes

Monica A Rixman Swinney

Kate Sapp

James R Pestisce

Dubravka Markvoic

Dave Thompson

Jason D McClure

Michael W Maccollum

Paul Daniel Faucher

William Wistar Rhoads

Rajan Ramaswamy

Michael J Dobbles

Michael Dobbles

Vance E Swanson

Antonio C Lievares

Amy DL Vandenberg

Amy D L Vandenberg

Amy D I Vandenberg

Jr Paul V Goode

Arnold L Holmquist

Mohammed Ali Shariati

Jake Leach

Devices and methods for treating obesity are provided. More particularly, intragastric devices and devices for inflating and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.

Pressure control system for intragastric device

Systems and methods of use involving sensors having a signal-to-noise ratio that is substantially unaffected by non-constant noise are provided for continuous analyte measurement in a host. In some embodiments, a continuous analyte measurement system is configured to be wholly, transcutaneously, intravascularly or extracorporeally implanted.

Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.

Intragastric device

An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication.

Integrated medicament delivery device for use with continuous analyte sensor

Intragastric volume-occupying devices and methods for treating obesity are provided. The devices, which are inflated by carbon dioxide, include an aluminum or silicon oxide barrier layer providing carbon dioxide retention and an alkylene vinyl alcohol polymer layer providing structural integrity in vivo.

Intragastric volume-occupying device and method for fabricating same

An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents.

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

Transcutaneous analyte sensor

An applicator for an analyte monitoring device may include an actuatable housing having a body defining a cavity therein and having a distal opening and a side opening. A cuff and a shuttle are received within the cavity and are separately translatable relative to the housing body. A base may removable engage the housing body at the distal opening. The housing body, the cuff, the shuttle, and/or the base may be engaged with one another with one or more releasable coupling features. The base may be removed from an engagement with the housing body, causing the cuff and the shuttle to be aligned and positioned in a configuration in which the analyte monitoring device, held by the shuttle, is ready for insertion into the skin.

Microneedle enclosure and applicator device for microneedle array based continuous analyte monitoring device

Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.

Analyte sensor

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, locating, tracking, monitoring, deflating, and retrieving the same are provided.

Systems and methods for determining failure of intragastric devices

Growing community of inventors

San Diego, CA, United States of America

Mark C Brister